Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study - Publication - Bridge of Knowledge

Your account

login

Search

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

Abstract

Citations

  • 6 5

    CrossRef

  • 0

    Web of Science

  • 6 7

    Scopus

Authors (18)

  • Photo of Gilles Salles

    Gilles Salles

  • Photo of Stephen Schuster

    Stephen Schuster

  • Photo of Sven de

    Sven de

  • Photo of Nina Wagner-Johnston

    Nina Wagner-Johnston

  • Photo of Andreas Viardot

    Andreas Viardot

  • Photo of Kristie Blum

    Kristie Blum

  • Photo of Christopher Flowers

    Christopher Flowers

  • Photo of MD, PhD, Prof Wojciech Jurczak

    Wojciech Jurczak MD, PhD, Prof

  • Photo of Ian Flinn

    Ian Flinn

  • Photo of Brad Kahl

    Brad Kahl

  • Photo of Peter Martin

    Peter Martin

  • Photo of Yeonhee Kim

    Yeonhee Kim

  • Photo of Sanatan Shreay

    Sanatan Shreay

  • Photo of Matthias Will

    Matthias Will

  • Photo of Bess Sorensen

    Bess Sorensen

  • Photo of Madlaina Breuleux

    Madlaina Breuleux

  • Photo of Pier Zinzani

    Pier Zinzani

  • Photo of Ajay Gopal

    Ajay Gopal

Cite as

Full text

full text is not available in portal

Details

Category:
Magazine publication
Type:
Magazine publication
Published in:
Haematologica-The Hematology Journal no. 102, edition 4, pages e156 - e159,
ISSN: 0390-6078
ISSN:
0390-6078
Publication year:
2017
DOI:
Digital Object Identifier (open in new tab) 10.3324/haematol.2016.151738
Verified by:
No verification

seen 86 times

Meta Tags